Asparagine

Asparagine

SCHEMBL366069

NC(=O)CC(N)C(=O)O.NC(CC(=O)O)C(=O)O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3

The experimentally established mechanism targets of Asparagine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
KMT2A Q03164 1/20 0.50
GRIK1 P39086 5/20 0.48
GRIK2 Q13002 3/20 0.48
GRM1 Q13255 2/20 0.48
GRM2 Q14416 2/20 0.48
SLC1A1 P43005 4/20 0.46
SLC1A3 P43003 3/20 0.46
SLC1A2 P43004 3/20 0.46
GRIA4 P48058 2/20 0.46
GRIK3 Q13003 2/20 0.46
GRIK5 Q16478 2/20 0.46
SLC7A5 Q01650 1/20 0.46
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GSR P00390 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asparagine SCHEMBL10011961 1.00 ALOX15 (0.50) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL7998952 1.00 ALOX15 (0.50) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL366070 1.00 ALOX15 (0.50) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL7998953 1.00 ALOX15 (0.50) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL6520765 0.98 ALOX15 (0.48) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL5327761 0.98 ALOX15 (0.48) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL7459478 0.93 ALOX15 (0.45) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL150535 0.92 ALOX15 (0.56) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL4347082 0.92 ALOX15 (0.56) ALOX15BLMPMP22KMT2AGRIK1
Asparagine SCHEMBL20489207 0.92 ALOX15 (0.56) ALOX15BLMPMP22KMT2AGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113310960-B Sulfur quantum dot synthesis method and sulfur quantum dot-based Fe determination method2+And H2O2Method (2) 四川中科微纳科技有限公司 2022-06-28 CN claimed
CN-113310960-A Sulfur quantum dot synthesis method and sulfur quantum dot-based Fe determination method+2And H2O2Method (2) 四川中科微纳科技有限公司 2021-08-27 CN claimed
CN-104271595-A Proteins toxic to hemipteran insect species MONSANTO TECHNOLOGY LLC 2015-01-07 CN claimed
US-20130116192-A1 N-(AMINOACYL)-AMINO COMPOUND WETH GOSBERT (DE) 2013-05-09 US claimed
EP-2358894-A1 TEST FOR PREDICTING NEUTRALIZATION OF ASPARAGINASE ACTIVITY Erytech Pharma (FR) 2011-08-24 EP claimed
WO-2010052315-A1 TEST FOR PREDICTING NEUTRALIZATION OF ASPARAGINASE ACTIVITY ERYTECH PHARMA (FR) 2010-05-14 WO claimed
CN-1600852-A Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B AMERICAN CYANAMID CO (US) 2005-03-30 CN claimed
CN-1294628-A Mutations causing attenuation of measles virus or human respiratory syncytial virus subgroup B AMERICAN CYANAMID CO (US) 2001-05-09 CN claimed
CN-1273603-A Attenuated respiratory syncytial virus AMERICAN CYANAMID CO (US) 2000-11-15 CN claimed
US-6048728-A PROPAGATING CELLS; CONTACTING CELLS WITH A CULTURE MEDIUM, WHEREIN SAID COMPONENTS ARE SUFFICIENT TO INCREASE THE CULTURES PRODUCTIVE SHELF LIFE BY MAINTAINING CELLS IN A PROPAGATION STATE CHIRON CORPORATION (US) 2000-04-11 US claimed
CN-1232504-A 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of order designated mononegavirales AMERICAN CYANAMID CO (US) 1999-10-20 CN claimed
EP-0332225-B1 ANTIBODY TO POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS HAVING AN AMINO ACID SEQUENCE OR NUCLEOTIDE CODING SEQUENCE AT LEAST PARTIALLY KNOWN AND METHODS OF DESIGN THEREFOR BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1993-04-21 EP claimed
US-20240181023-A1 FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS PERSEO PHARMA AG (CH) 2024-06-06 US disclosed
US-20240150752-A1 METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-09 US disclosed
US-20240141330-A1 METHODS AND COMPOSITIONS FOR MUTAGENESIS SCREENING IN MAMMALIAN CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-02 US disclosed
CN-117813378-A Compositions and methods for in vivo protease profiling by immunocyte display 乔治亚技术研究公司 2024-04-02 CN disclosed
EP-0269220-A2 Derivatives of alpha-hANP and their production Takeda Chemical Industries, Ltd. (JP) 1988-06-01 EP disclosed
CN-86106522-A Expression and Secretion of Heterologous Proteins Using Yarrowia lipolytica Transformants 1987-09-16 CN disclosed
CN-86102644-A Expression of factor VII and IX Activity in mammalian cells 1987-06-03 CN disclosed
WO-1985001746-A1 THE MANUFACTURE AND EXPRESSION OF GENES FOR THAUMATIN BEATRICE COMPANIES, INC. (US) 1985-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116192-A1 N-(AMINOACYL)-AMINO COMPOUND ASS1, AADAT, ARGLU1 ALOX15 4356/4885BLM 3567/4885PMP22 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.